volume 23, issue 11, P7427-7437 2019
DOI: 10.1111/jcmm.14609
View full text
|
Sign up to set email alerts
|
Share

Abstract: Abstract DYRK1A is considered a potential cancer therapeutic target, but the role of DYRK1A in NSCLC oncogenesis and treatment requires further investigation. In our study, high DYRK1A expression was observed in tumour samples from patients with lung cancer compared with normal lung tissues, and the high levels of DYRK1A were related to a reduced survival time in patients with lung cancer. Meanwhile, the DYRK1A inhibitor harmine could suppress the proliferation of NSCLC cells compared to that of the control. …

Expand abstract

Search citation statements

Order By: Relevance

Citation Types

0
10
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals